中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 11
Nov.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(11): 2669-2672

Correlation of systemic immune-inflammation index and pancreatic cancer prognosis, recent research progress

DOI: 10.3969/j.issn.1001-5256.2022.11.046
  • 1.

    College of Clinical Medical, North Sichuan Medical College, Nanchong, Sichuan 637000, China

  • 2.

    The PLA Center of General Surgery, General Hospital of Western Theater Command, Chengdu 610083, China

  • 3.

    Institute for Disaster Management and Reconstruction, Sichuan University, Chengdu 610207, China

Research funding:

National Clinical Key Subject of China (41732113)

More Information
  • Corresponding author: TANG Lijun, tanglj2016@163.com(ORCID: 0000-0001-6000-9515)
  • Received Date: 2022-03-14
  • Accepted Date: 2022-05-12
  • Published Date: 2022-11-20
    Abstract
  • Inflammation is associated with cancer development and plays a crucial role in pancreatic cancer progression. Inflammatory cell infiltration in the tumor lesion is a part of the tumor microenvironment, which could promote tumor cell proliferation, invasion, and metastasis. Recently developed systemic immune-inflammation index (SII) based on level of neutrophils, lymphocytes, and platelets was used to predict prognosis of cancer patients, including pancreatic cancer patients. This review summarized and discussed recent research progress on correlation of systemic immune-inflammation index and pancreatic cancer prognosis to provide appropriate treatment selections.

     

    • FullText(HTML)
  • loading
    • References(43)
  • [1]
    ZHU XZ, LI H, XU HX, et al. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021[J]. China Oncol, 2022, 32(1): 1-12. DOI: 10.19401/j.cnki.1007-3639.2022.01.001.

    朱鑫哲, 李浩, 徐华祥, 等. 2021年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2022, 32(1): 1-12. DOI: 10.19401/j.cnki.1007-3639.2022.01.001.
    [2]
    RAHIB L, SMITH BD, AIZENBERG R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74(11): 2913-2921. DOI: 10.1158/0008-5472.CAN-14-0155.
    [3]
    OKITSU K, KANDA T, IMAZEKI F, et al. Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer[J]. Genes Cancer, 2010, 1(8): 859-867. DOI: 10.1177/1947601910383417.
    [4]
    GUERRA C, COLLADO M, NAVAS C, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence[J]. Cancer Cell, 2011, 19(6): 728-739. DOI: 10.1016/j.ccr.2011.05.011.
    [5]
    GUERRA C, SCHUHMACHER AJ, CAÑAMERO M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice[J]. Cancer Cell, 2007, 11(3): 291-302. DOI: 10.1016/j.ccr.2007.01.012.
    [6]
    KIRKEGÅRD J, MORTENSEN FV, CRONIN-FENTON D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and Meta-analysis[J]. Am J Gastroenterol, 2017, 112(9): 1366-1372. DOI: 10.1038/ajg.2017.218.
    [7]
    EVANS A, COSTELLO E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion[J]. Front Physiol, 2012, 3: 270. DOI: 10.3389/fphys.2012.00270.
    [8]
    WANG C, NING K, HU HH, et al. Research progress in tumor microenvironment of pancreatic cancer[J]. Chin J Dig Surg, 2020, 19(1): 109-112. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.018.

    王超, 宁克, 胡欢欢, 等. 胰腺癌肿瘤微环境的研究进展[J]. 中华消化外科杂志, 2020, 19(1): 109-112. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.018.
    [9]
    AZIZ MH, SIDERAS K, AZIZ NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study[J]. Ann Surg, 2019, 270(1): 139-146. DOI: 10.1097/SLA.0000000000002660.
    [10]
    ZHANG SS. Clinicopathological features and outcomes of pancreatic cancer/Hsa_circ_0007564: a novel diagnostic and prognostic marker for pancreatic cancer[D]. Beijing: Peking Union Medical College, 2018.

    张水生. 胰腺癌临床病理特点及预后/Hsa_circ_0007564: 胰腺癌诊断和预后新的标志物[D]. 北京: 北京协和医学院, 2018.
    [11]
    ZHANG K, HUA YQ, WANG D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer[J]. J Transl Med, 2019, 17(1): 30. DOI: 10.1186/s12967-019-1782-x.
    [12]
    Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the diagnosis and treatment of pancreatic cancer in China(2021)[J]. Chin J Dig Surg, 2021, 20(7): 713-729. DOI: 10.3760/cma.j.cn115610-20210618-00289.

    中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南(2021)[J]. 中华消化外科杂志, 2021, 20(7): 713-729. DOI: 10.3760/cma.j.cn115610-20210618-00289.
    [13]
    ZHAO Y, CHENG J. Relationship between the systemic immune-inflammation index and the prognosis of pancreatic ductal adenocarcinoma patients after neoadjuvant chemotherapy[J]. Chin J Oncol Prev Treat, 2020, 12(2): 222-227. DOI: 10.3969/j.issn.1674-5671.2020.02.21.

    赵阳, 程静. 系统免疫炎症指数与接受新辅助化疗胰腺导管腺癌患者预后的关系[J]. 中国癌症防治杂志, 2020, 12(2): 222-227. DOI: 10.3969/j.issn.1674-5671.2020.02.21.
    [14]
    MURTHY P, ZENATI MS, AL ABBAS AI, et al. Prognostic value of the systemic immune-inflammation index (SⅡ) after neoadjuvant therapy for patients with resected pancreatic cancer[J]. Ann Surg Oncol, 2020, 27(3): 898-906. DOI: 10.1245/s10434-019-08094-0.
    [15]
    SHANG J, HAN X, ZHA H, et al. Systemic immune-inflammation index and changes of neutrophil-lymphocyte ratio as prognostic biomarkers for patients with pancreatic cancer treated with immune checkpoint blockade[J]. Front Oncol, 2021, 11: 585271. DOI: 10.3389/fonc.2021.585271.
    [16]
    ZHOU FQ, CHEN S, SUN HY, et al. Prognostic value of the systemic immune-inflammation index in patients with pancreatic cancer: a systematic review and Meta-analysis[J]. Chin J Gen Surg, 2020, 29(9): 1076-1083. DOI: 10.7659/j.issn.1005-6947.2020.09.007.

    周发权, 陈师, 孙红玉, 等. 系统免疫炎症指数与胰腺癌患者预后关系的系统评价和Meta分析[J]. 中国普通外科杂志, 2020, 29(9): 1076-1083. DOI: 10.7659/j.issn.1005-6947.2020.09.007.
    [17]
    LI X, LIN H, OUYANG R, et al. Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: a meta-analysis[J]. Biosci Rep, 2021, 41(8): BSR20204401. DOI: 10.1042/BSR20204401.
    [18]
    DINH HQ, EGGERT T, MEYER MA, et al. Coexpression of CD71 and CD117 identifies an early unipotent neutrophil progenitor population in human bone marrow[J]. Immunity, 2020, 53(2): 319-334. e6. DOI: 10.1016/j.immuni.2020.07.017.
    [19]
    FRIDLENDER ZG, SUN J, KIM S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN[J]. Cancer Cell, 2009, 16(3): 183-194. DOI: 10.1016/j.ccr.2009.06.017.
    [20]
    SHOJAEI F, WU X, ZHONG C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis[J]. Nature, 2007, 450(7171): 825-831. DOI: 10.1038/nature06348.
    [21]
    INO Y, YAMAZAKI-ITOH R, SHIMADA K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer[J]. Br J Cancer, 2013, 108(4): 914-923. DOI: 10.1038/bjc.2013.32.
    [22]
    NIELSEN SR, STRØBECH JE, HORTON ER, et al. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade[J]. Nat Commun, 2021, 12(1): 3414. DOI: 10.1038/s41467-021-23731-7.
    [23]
    WANG QQ, ZHENG JY, NI QC, et al. Prognostic significance of CXCR2 expression in pancreatic ductal carcinoma[J]. Natl Med J China, 2014, 94(48): 3805-3808. DOI: 10.3760/cma.j.issn.0376-2491.2014.48.004.

    王庆庆, 郑金榆, 倪启超, 等. CXCR2在胰腺导管癌组织中的表达与患者预后关系[J]. 中华医学杂志, 2014, 94(48): 3805-3808. DOI: 10.3760/cma.j.issn.0376-2491.2014.48.004.
    [24]
    HOSOI F, IZUMI H, KAWAHARA A, et al. N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression[J]. Cancer Res, 2009, 69(12): 4983-4991. DOI: 10.1158/0008-5472.CAN-08-4882.
    [25]
    JUNG HS, GU J, KIM JE, et al. Cancer cell-induced neutrophil extracellular traps promote both hypercoagulability and cancer progression[J]. PLoS One, 2019, 14(4): e0216055. DOI: 10.1371/journal.pone.0216055.
    [26]
    ALBRENGUES J, SHIELDS MA, NG D, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice[J]. Science, 2018, 361(6409): eaao4227. DOI: 10.1126/science.aao4227.
    [27]
    STEELE CW, KARIM SA, LEACH J, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma[J]. Cancer Cell, 2016, 29(6): 832-845. DOI: 10.1016/j.ccell.2016.04.014.
    [28]
    JIN W, YIN H, LI H, et al. Neutrophil extracellular DNA traps promote pancreatic cancer cells migration and invasion by activating EGFR/ERK pathway[J]. J Cell Mol Med, 2021, 25(12): 5443-5456. DOI: 10.1111/jcmm.16555.
    [29]
    TAKEMOTO A, MIYATA K, FUJITA N. Platelet-activating factor podoplanin: from discovery to drug development[J]. Cancer Metastasis Rev, 2017, 36(2): 225-234. DOI: 10.1007/s10555-017-9672-2.
    [30]
    OBERMEIER HL, RIEDL J, AY C, et al. The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study[J]. Res Pract Thromb Haemost, 2019, 3(3): 503-514. DOI: 10.1002/rth2.12197.
    [31]
    SABRKHANY S, KUIJPERS M, KNOL JC, et al. Exploration of the platelet proteome in patients with early-stage cancer[J]. J Proteomics, 2018, 177: 65-74. DOI: 10.1016/j.jprot.2018.02.011.
    [32]
    DUAN B, HU J, LIU H, et al. Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk[J]. Int J Cancer, 2018, 142(7): 1322-1331. DOI: 10.1002/ijc.31171.
    [33]
    MITRUGNO A, SYLMAN JL, NGO AT, et al. Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC[J]. Am J Physiol Cell Physiol, 2017, 312(2): C176-C189. DOI: 10.1152/ajpcell.00196.2016.
    [34]
    ELASKALANI O, FALASCA M, MORAN N, et al. The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance[J]. Cancers (Basel), 2017, 9(10): 142. DOI: 10.3390/cancers9100142.
    [35]
    KHORANA AA, HU YC, RYAN CK, et al. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer[J]. J Gastrointest Surg, 2005, 9(7): 903-911. DOI: 10.1016/j.gassur.2005.06.021.
    [36]
    JIMENEZ RE, HARTWIG W, ANTONIU BA, et al. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control[J]. Ann Surg, 2000, 231(5): 644-654. DOI: 10.1097/00000658-200005000-00004.
    [37]
    MIYASHITA T, TAJIMA H, MAKINO I, et al. Metastasis-promoting role of extravasated platelet activation in tumor[J]. J Surg Res, 2015, 193(1): 289-294. DOI: 10.1016/j.jss.2014.07.037.
    [38]
    JANG JE, HAJDU CH, LIOT C, et al. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer[J]. Cell Rep, 2017, 20(3): 558-571. DOI: 10.1016/j.celrep.2017.06.062.
    [39]
    CARSTENS JL, CORREA DE SAMPAIO P, YANG D, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer[J]. Nat Commun, 2017, 8: 15095. DOI: 10.1038/ncomms15095.
    [40]
    LI J, BYRNE KT, YAN F, et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy[J]. Immunity, 2018, 49(1): 178-193. e7. DOI: 10.1016/j.immuni.2018.06.006.
    [41]
    CASTINO GF, CORTESE N, CAPRETTI G, et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma[J]. Oncoimmunology, 2016, 5(4): e1085147. DOI: 10.1080/2162402X.2015.1085147.
    [42]
    LEE HS, LEEM G, KANG H, et al. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma[J]. J Gastroenterol Hepatol, 2021, 36(2): 516-522. DOI: 10.1111/jgh.15265.
    [43]
    LIN M, LIANG S, WANG X, et al. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage Ⅲ/IV) pancreatic cancer: a promising treatment[J]. J Cancer Res Clin Oncol, 2017, 143(12): 2607-2618. DOI: 10.1007/s00432-017-2513-4.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (377) PDF downloads(34) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return